Periodic Migrainous Neuralgia JOHN I. BALLA,* M.B., M.R.C.P.ED.; JOHN N. WALTON,t M.D., F.R.C.P. Brit. med. ., 1964, 1, 219-221 Periodic migrainous neuralgia is a clearly defined syndrome and excellent descriptions of it have been given by a number of authors (Harris, 1926 (Harris, , 1936 Horton et al., 1939 ; Horton, 1941 ; Ekbom, 1947; Kunkle et al., 1952; Symonds, 1956; Bickerstaff, 1959) . Its clinical features are usually so characteristic that its diagnosis should present no more difficulty than that of trigeminal neuralgia or classical migraine. Various treatments have been advised in the past, and, in particular, Ekbom (1947) , Symonds (1956) , and Bickerstaff (1959) have described their experience with prophylactic ergotamine preparations. Bickerstaff (1959) suggested that the syndrome was well defined but not widely recognized and that it is often misdiagnosed. He suggested that by describing it in a medical journal with a wide circulation it should become better known and many of the diagnostic difficulties would disappear.
We discovered that in our patients the average time from onset of symptoms to diagnosis was 6.5 years; hence it is clear that no remarkable change has occurred in the speed of diagnosis since Bickerstaff's paper appeared, and we therefore decided to review our own experience. We have done this in two ways: first, we give a brief review of the clinical picture as we have seen it, and then the results of treatment are reviewed.
The best description of the essential features of the syndrome was given by Sir Charles Symonds (1956) . We can do no better than quote from this classic paper, which appeared under the title, "A Particular Variety of Headache " ". . occurrence of paroxysms of headache, that is to say, pain of sudden onset and transitory duration, which occur in bouts lasting as a rule for several weeks with long intervals of perfect freedom. In the paroxysm the pain is felt mainly in the supra-orbital region or in and behind the eye, though it may spread beyond this region. It is, however, strictly unilateral. It is of agonizing severity, but very rarely lasts longer than two hours and often less. During a bout there is usually at least one paroxysm in each twenty-four hours; there may be more. In the intervals between paroxysms there is complete relief. The bout having ended, there is no further complaint of headache until the occurrence of the next bout after an interval of freedom, which is rarely less than six months and may be several years. No local cause for the pain is to be discovered...
Material and Methods
We have followed up all the cases of periodic migrainous neuralgia seen in the neurological out-patient department of the Newcastle General Hospital and of the Royal Victoria Infirmary, Newcastle upon Tyne, over a five-year period. Twenty-eight such cases were seen during this period, whereas in the same period 399 cases of migraine were seen. The period of follow-up varied from one month to five years, with an average of 2.5 years. We were unable to trace four patients.
Clinical Picture
There were 22 males and 6 females in the series, a strong male preponderance. The age distribution (Table I) Eight patients in our series did not receive treatment in the form of prophylactic ergotamine preparations because they were seen after their last bout, and none of them returned to the clinic to report that another bout was beginning. Three of these were lost in the follow-up. Of these eight cases, most had received ergotamine preparations at the beginning of an attack, and all reported shortening of the duration of the attack but without complete relief.
Twenty patients received prophylactic ergotamine preparations. They were all prescribed " migril " tablets (ergotamine tartrate 2 mg., cyclizine hydrochloride 50 mg., caffeine 100 mg. per tablet). The tablets were taken regularly two or three times a day and not at the beginning of an attack. If the attacks occurred at regular times of the day-for instance, in the early hours of the morning-then in some patients an additional migril tablet was given a few hours prior to the onset of the expected headache. The results are summarized in Table III . It will be seen that all patients received some relief. In six patients, though the relief was not complete, it was substantial. They all stated that the headaches became shorter and less severe. Two of these patients had the chronic form of migrainous neuralgia with attacks going on between their bouts. Both were also treated with subcutaneous ergotamine tartrate injections, and though they received more benefit from this than from the migril tablets they did not obtain complete relief. Ergot Possible complications were noted in only three patients: one noticed Raynaud's phenomenon affecting the fingers, one complained of irritability, and one complained of depression. Since the latter two symptoms are non-specific it is difficult to know whether these were side-effects of the treatment.
At the follow-up examination it was noted that among the 14 patients who obtained complete relief with migril there were four who did not carry on with it in all their bouts. In most cases the reason was that the patient's general practitioner did not prescribe it again, but one patient stated that he was "simply tired of taking tablets."
Discussion
The clinical picture as we saw it was identical with the descriptions given by others. It is therefore somewhat surprising that the average period between the time of onset and diagnosis was still six and a half years in our series. We feel that the reason is that the syndrome is still not sufficiently well recognized and that descriptions occurring in many standard textbooks are too indefinite or brief. Another possible reason suggested by Symonds (1956) and quoted by Bickerstaff (1959) is that this syndrome in the past has been described under a large variety of names. Sluder (1908) referred to the syndrome under the title of sphenopalatine ganglion neuralgia. It was discussed under the same name by Eagle (1942) . Harris (1926) described it under the heading, " ciliary migrainous neuralgia." Vail (1932) gave the syndrome the title of vidian neuralgia. Harris (1936) was the first to refer to it as migrainous neuralgia. Horton et al. (1939) called it erythromelalgia of the head, and Horton (1941) renamed it histaminic cephalgia. It was later referred to as petrosal neuralgia (Gardner et al., 1947) and as cluster headaches (Kunkle et al., 1952) . While many of the descriptions given by these authors do not present a complete picture of this syndrome, it is our view that they would all be embraced by it. We feel that early diagnosis is particularly important, because this is an extremely disabling condition and it is responsive to treatment. As can be seen, most patients respond to migril without any significant side-effects, and those who did not respond do well with prophylactic subcutaneous ergotamine tartrate. Recently good reports have appeared on the use of methysergide (Lance et al., 1963 ; Friedman, 1963) . We were also impressed by the results with this drug in the few patients to whom we had an opportunity to give it. In future, therefore, if we find that migril is ineffective, we feel that methysergide should be the second line of attack. MEBITALJOSHRNAL (921 Ekbom (1947) using " gynergen "1 reported results similar to our own. It has been our impression that gastro-intestinal side-effects were less marked with migril than with other preparations, but we have no statistically valid evidence to support this view. We are unable to throw any light on the aetiology of this condition. We see no reason why it should be attributed to histamine allergy and it is also difficult to relate it to migraine. In our cases a family history of migraine was rarely obtained, and this would be unexpected if this condition was indeed a variant of the migraine syndrome in which a positive family history is the rule rather than the exception. The age and sex distribution is also somewhat different from that of migraine, many of our patients having had their first symptoms in their forties. Though these are only two facets of the clinical picture, they may be of possible significance in distinguishing this syndrome from migraine. Summary Twenty-eight cases of periodic migrainous neuralgia are reviewed. The cermical picture is described. The average time which elapsed between the onset of symptoms and accurate I Known in Great Britain as " femergen." diagnosis was 6.5 years. Our experiences of treatment using prophylactic migril in 20 patients are discussed. In 14 the response was satisfactory and in six relief was only slight. Two of these patients showed further improvement on prophylactic ergotamine injections. Three patients who failed to respond to oral ergotamine or relapsed responded to methysergide. A plea is made for early diagnosis in this eminently treatable condition.
We are grateful to Dr. Henry Miller for allowing us to review a number of patients who were under his care.
Ergotamine tartrate has been the drug of choice for the symptomatic treatment of migraine for many years (Brock, et al., 1934) , and the vasoconstrictive action which is the basis of its use was clearly demonstrated by Graham and Wolff (1937) . Unfortunately ergotamine given orally has been shown to be less effective than when given by the parenteral or rectal route (Lennox and von Storch, 1935; Tunis and Wolff, 1953; Greene, 1959) . Because the practical difficulties associated with ergotamine injections and suppositories limit their use, alternative routes of administration have been sought and a formulation of ergotamine tartrate suitable for oral inhalation (" medihaler-ergotamine ") has recently been devised. Although a number of workers from other countries have reported favourably on its use (Finch, 1960; Graham et al., 1960; Blumenthal and Fuchs, 1961 ; Sutherland and Eadie, 1961 ; DalsgaardNielsen, 1961) their opinions were, in the main, based on uncontrolled observations. The present paper gives the results of a clinical trial of inhaled ergotamine tartrate in the treatment of migraine in which the therapeutic effectiveness of inhalation has been compared with that of the drug given sublingually. The trial was designed to solve the problem posed by a comparison of two different forms of administration of the same drug, as measured by a highly subjective response, by the use of a " double-blind " sequential procedure.
Selection of Patients.-Patients were accepted for inclusion in the trial if they satisfied the following criteria: (1) the duration of complaint of episodic headache had to exceed two years; (2) a family history of episodic headache had to be present; (3) the patient had to have on average two or more attacks of headache monthly; (4) the headache had to have a unilateral element; (5) one or more of the following symptoms had to be associated with the headache; nausea, vomiting, photophobia, diplopia, scotomata, blurring of vision, fortification spectra, paraesthesiae ; and (6) physical signs of neurological disease had to be absent.
Procedure for Inhalation of Ergotamine Tartrate.-A convenient portable apparatus for the self-administration of micronized ergotamine tartrate suspended in an inert aerosol propellant (medihaler-ergotamine) was used. The device was calibrated to deliver a fixed dose of 0.36 mg. of ergotamine tartrate per single inhalation. Each patient was taught how to use the device and given both verbal and written instructions to take one inhalation as soon as possible after the onset of a headache, with further single inhalations every 5 to 10 minutes until the headache had gone or a maximum of five inhalations had been reached. The procedure was not to be repeated within 24 hours. The maximum dose of ergotamine tartrate which could be taken during the first hour of an attack was thus 1.8 mg.
Procedure for the Sublingual Administration of Ergotamine Tartrate.-Tablets containing 1 mg. of ergotamine tartrate were used. Each patient was instructed to place one tablet beneath the tongue as soon as possible after the onset of the headache and to allow the tablet to dissolve. The average dissolution time of the tablets was five minutes. If the headache had not gone within half an hour another tablet was to be taken. No 
